Covered Stocks

Christopher Neyor

Work Rating Distribution Performance Price Targets & Ratings Chart

Analyst Christopher Neyor works at JPMORGAN and is focused on the Healthcare sector with 22 price targets and ratings documented since 2017 spanning on 2 stocks. Analyst's average stock valuation to be materialised ratio is 41.67% with an average time for price targets to be met of 91.5 days.

Most recent stock forecast was given on KALA, Kala Pharmaceuticals, Inc at 30-Mar-2022.

Christopher Neyor best performing recommendations are on PCRX (PACIRA BIOSCIENCES, INC).
The best stock recommendation documented was for PCRX (PACIRA BIOSCIENCES, INC) at 11/2/2018. The price target of $50 was fulfilled within 3 days with a profit of $0.32 (0.64%) receiving and performance score of 2.12.

Average potential price target upside

Currently, out of the existing stock ratings of Christopher Neyor - 854 which are a Buy (48.03%), 116 which are a Sell (6.52%), 808 which are a Hold (45.44%)

PCRX KALA

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average time for PT to be met

Performance score

Buy

71

$31.86 (81.40%)

69

26 days ago

9/17 (52.94%)

$16.87 (36.05%)

236

Buy

60

$20.86 (53.30%)

63

27 days ago

9/15 (60%)

$17.34 (37.22%)

291

Buy

60

$20.86 (53.30%)

94

1 months 24 days ago

3/19 (15.79%)

$39.74 (81.67%)

1358

Hold

52

$12.86 (32.86%)

60

2 months 21 days ago

25/28 (89.29%)

$1.94 (3.07%)

65

Buy

80

$40.86 (104.39%)

90

8 months 6 days ago

16/21 (76.19%)

$12.87 (26.89%)

391

Show more analysts
PCRX KALA